MAP1LC3B and acute myeloid leukemia: Consistently, the multiple-variable survival analysis reported in Figure 4C,D depicts that AML patients with high BECN1/high MAP1LC3B and high MAP1LC3B/low SQSTM1 expression profiles (indicative of active autophagy) display better prognosis (p = 0.0440 vs. p = 0.0303, respectively).